Update on the role of topotecan in the treatment of recurrent ovarian cancer

Oncologist

Volumn 7, Issue SUPPL. 5, 2002, Pages 3-10

  Herzog, Thomas J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Efficacy; Ovarian neoplasms; Paclitaxel; Recurrence; Topotecan

Indexed keywords

DOXORUBICIN; PACLITAXEL; TOPOTECAN;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CROSS RESISTANCE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0036390879     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-suppl_5-3     Document Type: Review

References (34)

1. Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Cornelison TL, Trimble EL, Kosary CL. SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988-1994. Gynecol Oncol 1999;74:350-355.
3. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita Jr. VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Sixth Edition. Philadelphia: Lippincott Williams & Wilkins, 2001;2:1597-1632.
4. Ozols RF. Update of the NCCN ovarian cancer practice guidelines. Oncology (Huntingt) 1997;11:95-105.
5. Kavanagh JJ, Kudelka AP, de Leon CG et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837-842.
6. Rose PG, Blessing JA, Mayer AR et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405-410.
7. Lund B, Hansen OP, Theilade K et al. Phase II study of gemcitabine (2′2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-1533.
8. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 2002;29:9-10.
9. Maurel J, Zorrilla M, Puertolas T et al. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 2001;12:713-717.
10. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-3322.
11. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-3061.
12. Kudelka AP, Tresukosol D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552-1557.
13. Swisher EM, Mutch DG, Rader JS et al. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997;66:480-486.
14. Bookman MA, Malmström H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-3352.
15. McGuire WP, Blessing JA, Bookman MA et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:1062-1067.
16. Hoskins P, Eisenhauer E, Beare S et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16:2233-2237.
17. Cesano A, Lane SR, Poulin R et al. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 1999;15:1233-1238.
18. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-2193.
19. Data on file. Philadelphia, PA: GlaxoSmithKline, 2001.
20. Gore M, ten Bokkel Huinink W, Carmichael J et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 2001;19:1893-1900.
21. Coleman RL. Emerging role of topotecan in front-line treatment of carcinoma of the ovary. The Oncologist 2002;7(suppl 5):46-55.
22. O'Reilly S, Rowinsky EK, Slichenmyer W et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996;14:3062-3073.
23. Armstrong D, O'Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. The Oncologist 1998;3:4-10.
24. European Agency for the Evaluation of Medicinal Products. CAELYX. Available at: http://www.eudra.org/humandocs/humans/EPAR/Caelyx/Caelyx.htm. Accessed May 1, 2002.
25. Markman M, Blessing JA, Alvarez RD et al. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2000;77:112-115.
26. Gerrits CJH, Schellens JHM, Burris H et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 1999;5:69-75.
27. Morris R, Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. The Oncologist 2002;7(suppl 5):29-35.
28. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998;34:1500-1508.
29. Aravantinos G, Zafiropoulos A, Bafaloukos D et al. Topotecan in heavily pretreated platinum resistant ovarian cancer patients. 10th Symposium of New Drugs in Cancer Therapy, Amsterdam, 1998:67.
30. Nielsen HA, Nielsen D, Engelholm SA. Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer. Gynecol Oncol 2000;77:383-388.
31. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001;83:257-262.
32. Möbus V, Pfaff PN, Volm T et al. Long time therapy with topotecan in patients with recurrence of ovarian carcinoma. Anticancer Res 2001;21:3551-3556.
33. Dunphy F, Boyd J, Dunleavy T. Paclitaxel and carboplatin in head and neck cancer. Semin Oncol 1997;24(suppl 19):S19-25-S19-27.
34. van den Bent MJ, van Putten WLJ, Hilkens PHE et al. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. Eur J Cancer 2002;38:387-391.